Q3 FY26: Standalone revenue up 24% YoY, 9M PAT falls on one-offs

Revenue Growth 20pctExceptional ItemResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.7%Reaction day

₹39.39

prior close

₹39.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+0.7% vs market

Pharmaceuticals peers, median of 159sector+0.4%+1.3% vs sector

On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+1.7

15m

+2.1

30m

+0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.7+1.0+0.7+0.4+1.3

Next day

+1.4+0.5+0.9+0.2+1.2

-1.0-0.0-0.9+0.0-1.0

-2.0-1.5-0.5-1.2-0.8

-3.7-2.2-1.5-1.7-2.0

-1.5-1.2-0.3-1.8+0.3

-3.6-2.4-1.2-2.5-1.0

15d

+2.8-8.8+11.7-7.0+9.8

+3.6-8.3+11.8-5.1+8.7

+2.1-3.5+5.6-3.5+5.6

+15.8+6.4+9.4+2.8+13.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Labs Q3 FY26 standalone revenue rose 24% YoY to Rs 457.57 crore. Consolidated Q3 revenue grew 14.5% to Rs 484.16 crore. But standalone 9M PAT nearly halved to about Rs 46 crore from Rs 93 crore, while consolidated 9M PAT fell about 21% YoY. Drag came from exceptional items and the deconsolidation of Dr Morepen Ltd, which ceased to be a subsidiary from July 31, 2025 after the parent's stake fell to 19.96%.

Likely market impact

Q3 topline strong, but 9M PAT sharply lower due to exceptional items and the loss of Dr Morepen Ltd as a subsidiary. Mixed signal.